We’re sorry. JavaScript is currently disabled in your browser, so you may not be able to fully experience the website. Please enable JavaScript to proceed.

About Endo Advantage™

Endo Advantage™ provides a single point of contact for healthcare professionals (HCP) and patients to help support patient access.

Once the decision to prescribe XIAFLEX® is made, acquisition services through Endo Advantage™ can assist you and your patients with:

INSURANCE
BENEFITS
INVESTIGATION

PRIOR
AUTHORIZATION

PATIENT FINANCIAL
ASSISTANCE
for those who qualify

To contact Endo Advantage™

Acquiring XIAFLEX®

Once REMS-certified, you can order XIAFLEX® through 1 of 3 channels

Only REMS-certified physicians and healthcare sites can acquire XIAFLEX®.

Purchase the product from our Specialty Distributor (SD) and bill patient's insurance for both XIAFLEX® and your professional services.

HOW IT WORKS:

1

HCP faxes Benefits Investigation/Rx form to Endo Advantage™

2

Endo Advantage™ conducts benefits verification

3

Endo Advantage™ sends benefits verification to HCP office

4

Endo Advantage™ sends vial order to SD upon physician request

5

SD confirms order and arranges delivery to HCP office

SD CONTACT INFORMATION

Besse Medical
1-800-543-2111 (phone)
1-800-543-8695 (fax)
www.besse.com

The Specialty Pharmacy Provider (SPP) will fill a patient-specific prescription for XIAFLEX®, bill the patient’s insurance for the product, and then ship it.

HOW IT WORKS:

1

HCP faxes Rx form and patient chart notes to Endo Advantage™

2

Endo Advantage™ conducts benefits verification and sends Rx form and benefits verification to SPP, as well as HCP

3

SPP confirms coverage

4

SPP collects consent and out-of-pocket payment from patient

5

SPP arranges delivery to HCP office

SPP CONTACT INFORMATION

US Bioservices
1-855-534-8323 (phone)
1-888-418-7246 (fax)
www.usbioservices.com

HCPs can acquire XIAFLEX® through the Hospital Pharmacy.

Patients can save with the Copay Assistance Program

With the XIAFLEX® Copay Assistance Program, eligible patients can receive up to $1200 toward their out-of-pocket cost for each vial of XIAFLEX®. Each treatment cycle includes 2 vials of XIAFLEX®, for a total savings per treatment cycle of up to $2400.

Some restrictions for patients apply. See restrictions, terms and conditions below.*

More than 95 percent of eligible patients paid zero dollars out of pocket with the XIAFLEX® Copay Assistance Program

Patient eligibility

Patients qualify for assistance under this program if:

  • They are receiving or have received XIAFLEX® for an approved indication and in a manner consistent with the instructions for administration of XIAFLEX®
  • They are uninsured or have insurance that is not provided by Medicare, Medicare Prescription Drug Benefit plans, Medicare Advantage, Veterans Affairs (VA), Medicaid, or similar federal or state programs, and this program is not otherwise prohibited by law
  • They are 18 years of age or older
  • They have paid or are obligated to pay out-of-pocket costs for a prescription of XIAFLEX®

No other purchase is necessary to receive this offer.

For more information, call 1-800-743-2382.

*Restrictions, Terms and Conditions

  1. By accepting this offer, you agree to report the value received under this offer to any health insurer or other third party paying for any part of your XIAFLEX® prescription if you are required to do so by benefit terms, contract, or law.

  2. This offer is not valid for prescriptions reimbursed in whole or in part by Medicare, Medicare Prescription Drug Benefit plans, Medicare Advantage, VA, Medicaid, or similar federal or state programs, or where otherwise prohibited by law.

  3. By accepting this offer, you agree that Endo Pharmaceuticals Inc. or those working on its behalf may contact your doctor to verify information about treatment that is relevant to verifying your eligibility for this offer.

  4. This offer is only valid for doses of XIAFLEX® administered in the US.

  5. This offer is valid for the out-of-pocket cost for a dose of XIAFLEX® only. Offer is not valid for any other products or other out-of-pocket costs (for example, office visit charges, office visit copays, or injection/administration costs), even if those costs are associated with the administration of a dose of XIAFLEX®.

  6. This offer is valid only if you have not used this program within the last 30 days.

  7. The selling, purchasing, trading, or counterfeiting of this offer is prohibited.

  8. Endo Pharmaceuticals Inc. reserves the right to rescind, revoke, or amend this offer without notice.

  9. By participating, you understand and agree to comply with the terms and conditions of this offer as set forth above.

†Based on analysis of over 4000 claims filed January 2015 through October 2015.

LEARN ABOUT TREATMENT WITH XIAFLEX®

See How It's Administered

ADDITIONAL XIAFLEX® RESOURCES TO HELP YOU AND YOUR PATIENTS

Explore the Resources Library

XIAFLEX® REPRESENTATIVES
ARE HERE TO HELP

Request a Representative
View All
▾
Collapse
▾

Important Safety
Information for XIAFLEX®

WARNING: CORPORAL RUPTURE (PENILE FRACTURE) OR OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE

Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX®‑treated patients in clinical studies. In other XIAFLEX®‑treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile "popping" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded. Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 (3.7%) XIAFLEX®‑treated patients.

Signs or symptoms that may reflect serious penile injury should be promptly evaluated to assess for corporal rupture or severe penile hematoma which may require surgical intervention.

Because of the risks of corporal rupture or other serious penile injury, XIAFLEX® is available for the treatment of Peyronie's disease only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XIAFLEX® REMS Program.

  • XIAFLEX® is contraindicated in the treatment of Peyronie's plaques that involve the penile urethra due to potential risk to this structure and in patients with a history of hypersensitivity to XIAFLEX® or to collagenase used in any other therapeutic application or application method
  • Injection of XIAFLEX® into collagen‑containing structures such as the corpora cavernosa of the penis may result in damage to those structures and possible injury such as corporal rupture (penile fracture). Therefore, XIAFLEX® should be injected only into the Peyronie's plaque and care should be taken to avoid injecting into the urethra, nerves, blood vessels, corpora cavernosa or other collagen‑containing structures of the penis
  • In the double‑blind, placebo‑controlled portions of the clinical trials in Peyronie's disease, a greater proportion of XIAFLEX®‑treated patients (4%) compared to placebo‑treated patients (1%) had localized pruritus after up to 4 treatment cycles (involving up to 8 XIAFLEX® injection procedures). The incidence of XIAFLEX®‑associated pruritus was similar after each injection regardless of the number of injections administered
  • Because XIAFLEX® contains foreign proteins, severe allergic reactions to XIAFLEX® can occur. Anaphylaxis was reported in a post‑marketing clinical trial in one patient who had previous exposure to XIAFLEX® for the treatment of Dupuytren's contracture. Healthcare providers should be prepared to address severe allergic reactions following XIAFLEX® injections. The safety of more than one treatment course of XIAFLEX® is not known
  • In the XIAFLEX® controlled trials in Peyronie’s disease, 65.5% of XIAFLEX®‑treated patients developed penile hematoma, and 14.5% developed penile ecchymosis. Patients with abnormal coagulation (except for patients taking low‑dose aspirin, eg, up to 150 mg per day) were excluded from participating in these studies. Therefore, the efficacy and safety of XIAFLEX® in patients receiving anticoagulant medications (other than low‑dose aspirin, eg, up to 150 mg per day) within 7 days prior to XIAFLEX® administration is not known. In addition, it is recommended to avoid use of XIAFLEX® in patients with coagulation disorders, including patients receiving concomitant anticoagulants (except for low‑dose aspirin)
  • In the XIAFLEX® clinical trials for Peyronie's disease, the most frequently reported adverse drug reactions (≥25%) and at an incidence greater than placebo included: penile hematoma, penile swelling, and penile pain

INDICATION

XIAFLEX® is indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

Please see the full Prescribing Information, including Boxed Warning and Medication Guide.

Reference:

1.  Data on file. DOF-XPD-05. Endo Pharmaceuticals Inc. Data compiled January 2015 through October 2015.